《大行報告》瑞信升綠葉製藥(02186.HK)評級至「跑贏大市」 目標價4.7元
瑞信發表研究報告,指綠葉製藥(02186.HK)旗下腫瘤線產品貝伐珠單抗注射液(LY01008)的上市許可申請已獲中國國家藥品監督管理局藥品審評中心受理。該行預期此藥品將在2021年獲批並推出市面。
該行指,貝伐珠單抗被批准用於治療肺癌和結腸直腸癌,均是中國最為常見的癌症。LY 01008的市場可比產品Avastin在2019年於中國的銷售達至約40億元人民幣。而貝伐珠單抗生物仿製藥具有相同的標籤及報銷範圍,預期將來可佔據可觀的市場分額。該行預期綠葉製藥的貝伐珠單抗銷售可在2021及2022年分別達至1.5億及4億元人民幣。
該行將公司的投資評級由原來的「中性」上調至「跑贏大市」,由於其LY01008的進度已可預期,將公司目標價維持在4.7元。然而,公司的股價自公布2019財年盈利業績以來已跌大約15%,相信其目前估值是被低估。隨著公司繼續將收入來源變得多元化,相信公司對於主要藥品「Lipusu」的潛在價格下跌會更具彈性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.